EGFR and non-small cell lung carcinoma: In the Phase III AURA3 trial (AZD9291 vs. Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer), osimertinib was superior to platinum therapy plus pemetrexed in patients with T790M whom the disease progressed during first-line EGFR-TKI therapy with a median PFS of 10.1 months, and objective response rate (ORR) of 71% (14).